Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome

Trial Profile

A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors Eleven Biotherapeutics; Sesen Bio
  • Most Recent Events

    • 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
    • 15 May 2014 Data was presented at the 2014 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, according to an Eleven Biotherapeutics media release.
    • 15 May 2014 Data was presented at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium, according to an Eleven Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top